TrialDrugs & aging2025

Benefit-Risk Assessment of Rivaroxaban in Older Patients With Nonvalvular Atrial Fibrillation or Venous Thromboembolism.

Paul P Dobesh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.